Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy
Lung Cancer International · 2015
DOI: 10.1155/2015/590148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer International, 2015. Verfasst von Mathieu D Saint-Pierre und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6 ; Department of Medicine, Queen's University, 102 Stuart Str…. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Malignant pleural mesothelioma (MPM) is associated with a poor prognosis. Palliative platinum-based chemotherapy may help to improve symptoms and prolong life. Since 2004, the platinum is commonly partnered with a folate antimetabolite. We performed a review investigating if survival had significantly changed before and after the arrival of folate antimetabolites in clinical practice.
Methods
All MPM patients from January 1991 to June 2012 were identified. Data collected included age, gender, asbestos exposure, presenting signs/symptoms, performance status, histology, stage, bloodwork, treatment modalities including chemotherapy, and date of death or last follow-up. The primary endpoint was overall survival. Cox models were applied to determine variables associated with survival.
Results
There were 245 patients identified. Median overall survival for all patients was 9.4 months. After multivariate analysis, performance status, stage, histology, leucocytosis, and thrombophilia remained independently associated with survival. Among all patients who received chemotherapy, there was no difference in overall survival between the periods before and after folate antimetabolite approval: 14.2 versus 13.2 months ( P = 0.35 ). Specifically receiving combined platinum-based/folate antimetabolite chemotherapy did not improve overall survival compared to all other chemotherapy regimens: 14.1 versus 13.6 months ( P = 0.97 ).
Conclusions
In this review, we did not observe an incremental improvement in overall survival after folate antimetabolites became available.
Autor:innen und Institutionen
- Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6 ; Department of Medicine, Queen's University, 102 Stuart Street, Kingston, ON, Canada K7L 2V6.
- Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6.
- The Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, ON, Canada K1Y 4E9.
Zitieren
APA
Saint-Pierre, M. D., Pease, C., Mithoowani, H., Zhang, T., Nicholas, G. A., Laurie, S. A., & Wheatley-Price, P. (2015). Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. Lung Cancer International. https://doi.org/10.1155/2015/590148
Vancouver
Saint-Pierre MD, Pease C, Mithoowani H, Zhang T, Nicholas GA, Laurie SA, et al. Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy. Lung Cancer International. 2015. doi:10.1155/2015/590148
BibTeX
@article{SaintPierre2015,
author = {Saint-Pierre, Mathieu D and Pease, Christopher and Mithoowani, Hamid and Zhang, Tinghua and Nicholas, Garth A and Laurie, Scott A and Wheatley-Price, Paul},
title = {Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy},
journal = {Lung Cancer International},
year = {2015},
doi = {10.1155/2015/590148}
}
EUVIMED